SOX方案联合特瑞普利单抗治疗中晚期混合型肝细胞胆管细胞癌1例

摘要
图/表
参考文献(26)
相关文章 (6)

全文: PDF (1750 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要混合型肝细胞胆管细胞癌（cHCC-CCA）是原发性肝癌中的罕见类型，兼具肝细胞肝癌和胆管细胞癌的分化特点，被认为是一种预后不良且生存率改善甚微的侵袭性肿瘤。对于不能切除的cHCC-CCA，其标准治疗方案目前证据有限，国内外相关报道较少。本文报道了1例在确诊时无法行根治性切除的ⅢB期cHCC-CCA患者，使用SOX化疗方案+特瑞普利单抗联合治疗15个周期后，最终达到病理学完全缓解的诊治过程。通过病例回顾性分析及文献复习，以期提高临床对cHCC-CCA的诊疗水平。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	何亚琳1 杨嘉欣1 程志强2

关键词 ：混合型肝细胞胆管细胞癌, SOX化疗方案, 特瑞普利单抗, 病理完全缓解, 病例报告

Abstract：Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare type of primary hepatocellular carcinoma, which has differentiation characteristics of hepatocellular carcinoma and cholangiocarcinoma, it is considered an aggressive tumor with poor prognosis and little improvement in survival. For unresectable cHCC-CCA, the evidence of standard treatment is limited, and there are few reports about it at home and abroad. This paper reports a case of stage ⅢB cHCC-CCA who was unable to undergo radical resection at the time of diagnosis, after 15 cycles of SOX chemotherapy plus terriprizumab, finally, the diagnosis and treatment process of complete pathological remission was achieved. In order to improve the clinical diagnosis and treatment level of cHCC-CCA, retrospective case analysis and literature review.

Key words： Combined hepatocellular-cholangiocarcinoma SOX chemotherapy protocol Toripalimab Pathological complete remission Case report

基金资助:北京市自然科学基金项目（7212194）。

通讯作者: 程志强（1968-），男，博士，主任医师，教授，博士生导师；研究方向：中西医结合防治恶性肿瘤。

作者简介: 何亚琳（1995-），女，北京中医药大学研究生院2019级中西医结合临床专业在读硕士研究生；研究方向：中西医结合防治恶性肿瘤。

引用本文:

何亚琳1 杨嘉欣1 程志强2. SOX方案联合特瑞普利单抗治疗中晚期混合型肝细胞胆管细胞癌1例[J]. 中国医药导报, 2022, 19(9): 181-184.
HE Yalin1 YANG Jiaxin1 CHENG Zhiqiang2. A case report of SOX regimen combined with terriprizumab in treatment of intermediate and advanced combined hepatocellular-cholangiocarcinoma#br#. 中国医药导报, 2022, 19(9): 181-184.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I9/181

[1] Wang AQ，Zheng YC，Du J，et al. Combined hepatocellular cholangiocarcinoma：Controversies to be addressed [J]. World J Gastroenterol，2016，22：4459-4465.
[2] Sempokuya T，Wien EA，Pattison RJ，et al. Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma [J]. World J Hepatol，2020，12（11）：1020-1030.
[3] Spolverato G，Bagante F，Tsilimigras D，et al. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma：A population-based analysis [J]. J Surg Oncol，2019，119（3）：278-287.
[4] Jung DH，Hwang S，Song GW，et al. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection [J]. Liver Transpl，2017，23（3）：330-341.
[5] Ramai D，Ofosu A，Lai JK，et al. Combined Hepatocellular Cholangiocarcinoma：A Population-Based Retrospective Study [J]. Am J Gastroenterol，2019，114（9）：1496-1501.
[6] Cong WM，Wu MC. New insights into molecular diagnostic pathology of primary liver cancer：Advances and challenges [J]. Cancer Lett，2015，368（1）：14-19.
[7] Wang J，Li E，Yang H，et al. Combined hepatocellular-cholangiocarcinoma：a population level analysis of incidence and mortality trends [J]. World J Surg Oncol，2019， 17（1）：43.
[8] Chen PD，Chen LJ，Chang YJ，et al. Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma：A Nationwide Study [J]. Oncologist，2021，26（10）：e1774-e1785.doi：10.1002/onco.13893
[9] Laohawetwanit T，Lerttanatum N，Wanpiyarat N，et al. Combined hepatocellular-cholangiocarcinoma and its mimickers：Diagnostic pitfalls in surgical pathology [J]. Ann Diagn Pathol，2021，53：151770.
[10] Chu KJ，Lu CD，Dong H，et al. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma：clinicopat-hological and prognostic analysis of 390 cases [J]. Eur J Gastroenterol Hepatol，2014，26（2）：192-199.
[11] Leoni S，Sansone V，Lorenzo SD，et al. Treatment of Combined Hepatocellular and Cholangiocarcinoma [J]. Cancers（Basel），2020，12（4）：794. DOI：10.3390/cancers12040794.
[12] Fowler K，Saad NE，Brunt E，et al. Biphenotypic primary liver carcinomas： assessing outcomes of hepatic directed therapy [J]. Ann Surg Oncol，2015，22（13）：4130-4137.
[13] Rogers JE，Bolonesi RM，Rashid A，et al. Systemic therapy for unresectable，mixed hepatocellular-cholangiocarcinoma：treatment of a rare malignancy [J]. J Gastrointest Oncol，2017，8（2）：347-351.
[14] Kobayashi S，Terashima T，Shiba S，et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma [J]. Cancer Sci，2018，109（9）：2549-2557.
[15] Finkelmeier F，Waidmann O，Trojan J. Nivolumab for the treatment of hepatocellular carcinoma [J]. Expert Rev Anticancer Ther，2018，18（12）：1169-1175.
[16] Rizell M，Aberg F，Perman M，et al. Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular Cholangiocarcinoma after Hepatic Resection [J]. Case Rep Oncol，2020，13（1）：478-484.
[17] Sheng XN，Yan XQ，Chi ZH，et al. Axitinib in Combination With Toripalimab，a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1，in Patients With Metastatic Mucosal Melanoma：An Open-Label Phase ⅠB Trial [J]. J Clin Oncol，2019，37（21）：2987-2999.
[18] Sheng X，Chen H，Yao X，et al. Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase Ⅱ clinical study [J]. J Clinical Oncology，2019，37(15_suppl)：4554-4554.
[19] Wang ZJ，Ying JM，Xu JC，et al. Safety，Antitumor Activity，and Pharmacokinetics of Toripalimab，a Programmed Cell Death 1 Inhibitor，in Patients With Advanced Non-Small Cell Lung Cancer：A Phase 1 Trial [J]. JAMA Netw Open，2020，3（10）：e2013770.
[20] Xing WQ，Zhao LD，Fu XM，et al. A phase Ⅱ，single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma [J]. J Thorac Dis，2020，12（11）：6861-6867.
[21] Benson AB，D’Angelica MI，Abbott DE，et al. Hepatobiliary Cancers，Version2.2021，NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2021，19（5）：541-565.
[22] Lee DW，Lee KH，Kim HJ，et al. A phase Ⅱ trial of S1 and oxaliplatin in patients with advanced hepatocellular carcinoma [J]. BMC Cancer，2018，18（1）：252.
[23] Brown JS，Sundar R，Lopez J. Combining DNA damaging the rapeutics with immunotherapy：more haste，less speed [J]. Br J Cancer，2018，118（3）：312-324.
[24] McGranahan N，Furness AJ，Rosenthal R，et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade [J]. Science，2016，351（6280）：1463.
[25] Ang C，Klempner SJ，Ali SM，et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma [J]. Oncotarget，2019，10（40）：4018-4025.
[26] Zhu AX，Finn RS，Edeline J，et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib （KEYNOTE-224）：a non-randomised，open-label phase 2 trial [J]. Lancet Oncol，2018，19（7）：940-952.